Comment on: An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab
Sir, It was with great interest we read the article "An unusual presentation of nonarteritic ischemic optic neuropathy (NAION) with subretinal fluid treated with intravitreal bevacizumab" by Dave and Pappuru. [1] We have noticed some points in the text and would like to put forth few queries which we feel were not addressed adequately in this article.
Diabetic status of the patient has not been mentioned. It is known that diabetes mellitus, apart from hypertension, is a predisposing factor for the development of NAION and the characteristics of such patients differ from nondiabetic patients with NAION. [2] We agree that macular edema is an unusual finding in NAION even in fundus fluorescein angiography (FFA) studies as mentioned by the authors. Yet the authors have not mentioned FFA findings in the article. We believe FFA of the affected eye is essential in cases of atypical NAION with sub retinal fluid (SRF) to rule out inflammatory pathologies. Other eye's visual fields, fundus image, FFA, and optical coherence tomography would have been helpful for comparison and to rule out any other pathologies. Improvement in visual acuity cannot be contributed to intravitreal bevacizumab with certainty as vision is known to improve, in >40% cases, with the natural history of disease. [3] Authors have documented 20/200 best-corrected visual acuity in other eye post-NAION. Hayreh and Zimmerman have shown the difference in final visual outcomes in eyes of patients with bilateral sequential NAION. [4] Low final vision in one eye cannot be used as a predictor of poor prognosis when other eye develops NAION and should not be an indication for interventional treatment.
Authors have documented an improvement in visual acuity but have not commented on the visual fields during follow-up.
We found two reports of intravitreal bevacizumab being associated with the development of NAION in literature and we are mentioning one due to the restriction of a number of references. [5] It is postulated to be due to the transient raised IOP caused by the injection affecting the already compromised optic disc. Keeping this in mind and the fact that NAION recovers to some extent in its natural history, we feel that this therapy needs to be proved through proper randomized trials before being tried in NAION patients.
Macular edema and subretinal fluid have also been described in literature and have been shown to resolve without use of any treatment. [2] We feel the presence of subretinal fluid or macular edema does not necessitate treatment in such cases.
The authors, Dave et al. have mentioned in their reference number 11 that the article on "Macular star in Optic neuropathy" by Wang AG, Lui JH, Lin CL, and Yen MY was published in "Am J Ophthalmol," when in fact it was published in "Annals of ophthalmology" in 1995.
The abstract mentions the last follow-up being at 6 months while text documents it as 3 months. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Authors' reply
Sir, We thank the readers for their observations about our case report. [1, 2] Our explanation to the raised concerns is mentioned below.
We accept and apologize for the typographical errors pointed out. Regarding the diabetic status of the patient not being mentioned, the readers have quoted an article citing differences between the diabetic and nondiabetic nonarteritic ischemic optic neuropathic (NAION) cases. We would like to point out that the concerned paper concludes no clinical difference between the initial visual acuity presentation and the final visual outcome. [3] Rather all significant clinical differences are only demographic.
Fundus fluorescein angiography (FFA) findings have not been mentioned as the invasive test was not done. FFA in our case would not have changed our diagnosis or management approach. Although FFA does assist in diagnosing inflammatory pathologies, the absence of findings such as vitreous cellularity, vascular cuffing and sheathing, cystoid changes at the fovea, and hemorrhages and exudates clinically rules out inflammation. Given the advanced age of the patient, hypertensive systemic status and optic atrophy with similar complaints in the past in the other eye, the diagnosis of NAION was most suggestive without the need for further testing.
In the article that they quote, visual acuity improvement in patients similar to our presentation is mentioned to be 40%, and hence the readers say that improvement in visual acuity cannot be contributed to intravitreal bevacizumab with certainty and could be a natural history-related improvement. [4] We observe that statistically speaking a proportional confidence interval for 40% in the mentioned article varies from 26.17% (improvement in the worst case scenario) to 57.7% (improvement in the best case scenario). Thus, treating for the worst case scenario seems justified. Visual field on follow-up was not documented as the patient did not consent for the same. In any case, our therapy was directed toward the central subretinal fluid on optical coherence tomography, and thus toward central visual acuity and not change in visual field. The reference that the readers mention about resolution of macular edema actually describes optic disc edema and does not clearly mention about macular edema. [4] Although a randomized trial as the readers mention is ideal, considering an incidence of NAION of 82/100,000 persons, the logistics are clearly prohibitive. [5] Financial support and sponsorship Nil.
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